Selected research
Industry Research
Neurodegenerative Disease IVD Industry Research Report 2026
Market perspective
The global Neurodegenerative Disease IVD market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Neurodegenerative Disease IVD market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Neurodegenerative Disease IVD market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Neurodegenerative Disease IVD market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Neurodegenerative Disease IVD include ADx Neurosciences, Analytik Jena, Beckman Coulter, Creative Biolabs, Fujirebio, Genemedi, Medix Biochemica, Revvity and Roche Diagnostics. among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Neurodegenerative Disease IVD market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Neurodegenerative Disease IVD.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Neurodegenerative Disease IVD Market by Company
ADx Neurosciences
Analytik Jena
Beckman Coulter
Creative Biolabs
Fujirebio
Genemedi
Medix Biochemica
Revvity
Roche Diagnostics
Neurodegenerative Disease IVD Segment by Type
Protein Biomarker Detection
Nucleic Acid Biomarker Detection
Others
Neurodegenerative Disease IVD Segment by Application
Alzheimer's Disease
Parkinson's Disease
Huntington's Disease
Amyotrophic Lateral Sclerosis (ALS)
Multiple System Atrophy (MSA)
Progressive Supranuclear Palsy (PSP)
Others
Neurodegenerative Disease IVD Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurodegenerative Disease IVD market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neurodegenerative Disease IVD and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurodegenerative Disease IVD.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Neurodegenerative Disease IVD companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Protein Biomarker Detection
- Nucleic Acid Biomarker Detection
- Others
Applications
- Alzheimer's Disease
- Parkinson's Disease
- Huntington's Disease
- Amyotrophic Lateral Sclerosis (ALS)
- Multiple System Atrophy (MSA)
- Progressive Supranuclear Palsy (PSP)
- Others
Companies covered
- ADx Neurosciences
- Analytik Jena
- Beckman Coulter
- Creative Biolabs
- Fujirebio
- Genemedi
- Medix Biochemica
- Revvity
- Roche Diagnostics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Neurodegenerative Disease IVD by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Protein Biomarker Detection
- 2.2.3 Nucleic Acid Biomarker Detection
- 2.2.4 Others
- 2.3 Neurodegenerative Disease IVD by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Alzheimer's Disease
- 2.3.3 Parkinson's Disease
- 2.3.4 Huntington's Disease
- 2.3.5 Amyotrophic Lateral Sclerosis (ALS)
- 2.3.6 Multiple System Atrophy (MSA)
- 2.3.7 Progressive Supranuclear Palsy (PSP)
- 2.3.8 Others
- 2.4 Assumptions and Limitations
3 Neurodegenerative Disease IVD Breakdown Data by Type
- 3.1 Global Neurodegenerative Disease IVD Historic Market Size by Type (2021-2026)
- 3.2 Global Neurodegenerative Disease IVD Forecasted Market Size by Type (2027-2032)
4 Neurodegenerative Disease IVD Breakdown Data by Application
- 4.1 Global Neurodegenerative Disease IVD Historic Market Size by Application (2021-2026)
- 4.2 Global Neurodegenerative Disease IVD Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Neurodegenerative Disease IVD Market Perspective (2021-2032)
- 5.2 Global Neurodegenerative Disease IVD Growth Trends by Region
- 5.2.1 Global Neurodegenerative Disease IVD Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Neurodegenerative Disease IVD Historic Market Size by Region (2021-2026)
- 5.2.3 Neurodegenerative Disease IVD Forecasted Market Size by Region (2027-2032)
- 5.3 Neurodegenerative Disease IVD Market Dynamics
- 5.3.1 Neurodegenerative Disease IVD Industry Trends
- 5.3.2 Neurodegenerative Disease IVD Market Drivers
- 5.3.3 Neurodegenerative Disease IVD Market Challenges
- 5.3.4 Neurodegenerative Disease IVD Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Neurodegenerative Disease IVD Players by Revenue
- 6.1.1 Global Top Neurodegenerative Disease IVD Players by Revenue (2021-2026)
- 6.1.2 Global Neurodegenerative Disease IVD Revenue Market Share by Players (2021-2026)
- 6.2 Global Neurodegenerative Disease IVD Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Neurodegenerative Disease IVD Head Office and Area Served
- 6.4 Global Neurodegenerative Disease IVD Players, Product Type & Application
- 6.5 Global Neurodegenerative Disease IVD Manufacturers Established Date
- 6.6 Global Neurodegenerative Disease IVD Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Neurodegenerative Disease IVD Market Size (2021-2032)
- 7.2 North America Neurodegenerative Disease IVD Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Neurodegenerative Disease IVD Market Size by Country (2021-2026)
- 7.4 North America Neurodegenerative Disease IVD Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Neurodegenerative Disease IVD Market Size (2021-2032)
- 8.2 Europe Neurodegenerative Disease IVD Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Neurodegenerative Disease IVD Market Size by Country (2021-2026)
- 8.4 Europe Neurodegenerative Disease IVD Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Neurodegenerative Disease IVD Market Size (2021-2032)
- 9.2 Asia-Pacific Neurodegenerative Disease IVD Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Neurodegenerative Disease IVD Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Neurodegenerative Disease IVD Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Neurodegenerative Disease IVD Market Size (2021-2032)
- 10.2 South America Neurodegenerative Disease IVD Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Neurodegenerative Disease IVD Market Size by Country (2021-2026)
- 10.4 South America Neurodegenerative Disease IVD Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Neurodegenerative Disease IVD Market Size (2021-2032)
- 11.2 Middle East & Africa Neurodegenerative Disease IVD Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Neurodegenerative Disease IVD Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Neurodegenerative Disease IVD Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 ADx Neurosciences
- 12.1.1 ADx Neurosciences Company Information
- 12.1.2 ADx Neurosciences Business Overview
- 12.1.3 ADx Neurosciences Revenue in Neurodegenerative Disease IVD Business (2021-2026)
- 12.1.4 ADx Neurosciences Neurodegenerative Disease IVD Product Portfolio
- 12.1.5 ADx Neurosciences Recent Developments
- 12.2 Analytik Jena
- 12.2.1 Analytik Jena Company Information
- 12.2.2 Analytik Jena Business Overview
- 12.2.3 Analytik Jena Revenue in Neurodegenerative Disease IVD Business (2021-2026)
- 12.2.4 Analytik Jena Neurodegenerative Disease IVD Product Portfolio
- 12.2.5 Analytik Jena Recent Developments
- 12.3 Beckman Coulter
- 12.3.1 Beckman Coulter Company Information
- 12.3.2 Beckman Coulter Business Overview
- 12.3.3 Beckman Coulter Revenue in Neurodegenerative Disease IVD Business (2021-2026)
- 12.3.4 Beckman Coulter Neurodegenerative Disease IVD Product Portfolio
- 12.3.5 Beckman Coulter Recent Developments
- 12.4 Creative Biolabs
- 12.4.1 Creative Biolabs Company Information
- 12.4.2 Creative Biolabs Business Overview
- 12.4.3 Creative Biolabs Revenue in Neurodegenerative Disease IVD Business (2021-2026)
- 12.4.4 Creative Biolabs Neurodegenerative Disease IVD Product Portfolio
- 12.4.5 Creative Biolabs Recent Developments
- 12.5 Fujirebio
- 12.5.1 Fujirebio Company Information
- 12.5.2 Fujirebio Business Overview
- 12.5.3 Fujirebio Revenue in Neurodegenerative Disease IVD Business (2021-2026)
- 12.5.4 Fujirebio Neurodegenerative Disease IVD Product Portfolio
- 12.5.5 Fujirebio Recent Developments
- 12.6 Genemedi
- 12.6.1 Genemedi Company Information
- 12.6.2 Genemedi Business Overview
- 12.6.3 Genemedi Revenue in Neurodegenerative Disease IVD Business (2021-2026)
- 12.6.4 Genemedi Neurodegenerative Disease IVD Product Portfolio
- 12.6.5 Genemedi Recent Developments
- 12.7 Medix Biochemica
- 12.7.1 Medix Biochemica Company Information
- 12.7.2 Medix Biochemica Business Overview
- 12.7.3 Medix Biochemica Revenue in Neurodegenerative Disease IVD Business (2021-2026)
- 12.7.4 Medix Biochemica Neurodegenerative Disease IVD Product Portfolio
- 12.7.5 Medix Biochemica Recent Developments
- 12.8 Revvity
- 12.8.1 Revvity Company Information
- 12.8.2 Revvity Business Overview
- 12.8.3 Revvity Revenue in Neurodegenerative Disease IVD Business (2021-2026)
- 12.8.4 Revvity Neurodegenerative Disease IVD Product Portfolio
- 12.8.5 Revvity Recent Developments
- 12.9 Roche Diagnostics
- 12.9.1 Roche Diagnostics Company Information
- 12.9.2 Roche Diagnostics Business Overview
- 12.9.3 Roche Diagnostics Revenue in Neurodegenerative Disease IVD Business (2021-2026)
- 12.9.4 Roche Diagnostics Neurodegenerative Disease IVD Product Portfolio
- 12.9.5 Roche Diagnostics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst